PMID- 17073837
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20240413
IS  - 1368-5031 (Print)
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 60
IP  - 11
DP  - 2006 Nov
TI  - Is ranitidine therapy sufficient for healing peptic ulcers associated with 
      non-steroidal anti-inflammatory drug use?
PG  - 1401-7
AB  - Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the 
      risk of serious gastroduodenal events. To minimise these risks, patients often 
      require concomitant acid-suppressive therapy. We conducted a literature review of 
      clinical trials examining use of ranitidine 150 mg twice daily to heal 
      gastroduodenal ulcers (GU) in NSAID recipients. Seven studies were identified. 
      After 8 weeks' treatment with ranitidine, GU healing rates ranged from 50% to 74% 
      and rates of duodenal ulcer (DU) healing ranged from 81% to 84%. Ranitidine was 
      more effective when NSAIDs were discontinued (healing rates reaching 95% and 
      100%, respectively). The ulcer healing rate with sucralfate was similar to that 
      of ranitidine. However, proton pump inhibitor (PPI) therapy was associated with 
      significantly greater rates of both GU and DU healing than ranitidine; 8-week GU 
      rates were 92% and 88% with esomeprazole 40 mg and 20 mg, respectively (vs. 74% 
      with ranitidine, p < 0.01). For omeprazole, 8-week healing rates were 87% with 
      omeprazole 40 mg and 84% with omeprazole 20 mg (vs. 64% for ranitidine, p < 
      0.001), and for lansoprazole the corresponding values were 73-74% and 66-69% for 
      the 30 mg and 15 mg doses, respectively (vs. 50-53% for ranitidine, p < 0.05). In 
      the PPI study reporting DU healing the values were 92% for omeprazole 20 mg (vs. 
      81% for ranitidine, p < 0.05) and 88% for omeprazole 40 mg (p = 0.17 vs. 
      ranitidine). NSAID-associated GU are more likely to heal when patients receive 
      concomitant treatment with a PPI rather than ranitidine.
FAU - Yeomans, N D
AU  - Yeomans ND
AD  - School of Medicine, University of Western Sydney, NSW, Australia. 
      n.yeomans@uws.edu.au
FAU - Svedberg, L-E
AU  - Svedberg LE
FAU - Naesdal, J
AU  - Naesdal J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 884KT10YB7 (Ranitidine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Arthritis/*drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Peptic Ulcer/chemically induced/*drug therapy
MH  - Proton Pump Inhibitors
MH  - Ranitidine/*therapeutic use
MH  - Treatment Outcome
PMC - PMC1636688
EDAT- 2006/11/01 09:00
MHDA- 2007/02/28 09:00
PMCR- 2006/03/27
CRDT- 2006/11/01 09:00
PHST- 2006/11/01 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2006/11/01 09:00 [entrez]
PHST- 2006/03/27 00:00 [pmc-release]
AID - IJCP1147 [pii]
AID - 10.1111/j.1742-1241.2006.01147.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2006 Nov;60(11):1401-7. doi: 10.1111/j.1742-1241.2006.01147.x.